青钱柳茶剂对糖尿病前期湿热蕴脾证的临床研究

目的:探讨青钱柳茶剂治疗糖尿病前期湿热蕴脾证临床疗效及潜在作用机制。方法：前瞻性纳入我院2022年1月-2022年12月收治糖尿病前期湿热蕴脾证患者共66例,采用随机抽签法分为两组,对照组33例给予基础生活干预治疗,试验组33例则在对照组基础上加用青钱柳茶剂治疗；比较两组治疗前后中医证候评分、空腹血糖水平、餐后2h血糖水平、糖化血红蛋白水平、胰高血糖素水平及安全性指标。结果：两组治疗后中医证候评分、空腹血糖、餐后2h血糖、糖化血红蛋白及胰高血糖素水平均显著低于治疗前(P<0.05)；试验组治疗后中医证候评分、空腹血糖、餐后2h血糖、糖化血红蛋白及胰高血糖素水平均显著低于同期对照组(P<0.05)；两组不良反应发生率组间比较差异无统计学意义(P>0.05)。结论：青钱柳茶剂治疗糖尿病前期湿热蕴脾证可有效控制血糖水平,且安全性良好；而该方案对于血糖水平更佳控制作用可能与其能够有效抑制胰高血糖素分泌有关。

Clinical study of Qingqian Willow Tea in the treatment of Shireyunpi type in prediabetes by inhibiting glucagon

Objective To investigate the clinical effects of Qingqian Willow Tea in the treatment of prediabetes patients with Shireyunpi type. Methods 66 prediabetes patients with Shireyunpi type were prospectively chosen in the period from January 2022 to December 2022 in our hospital and randomly divided into two groups by drawing lots including control group(33 cases) with given basic life intervention treatment and experiment group(33 cases)with Qingqian Willow tea on the basis of control group. The TCM syndrome score, fasting blood glucose level, 2h postprandial blood glucose level, glycosylated hemoglobin level, glucagon level before and after treatment and safety indexes of 2 groups were compared. Results The TCM syndrome score, fasting blood glucose, 2h postprandial blood glucose, glycosylated hemoglobin and glucagon levels after treatment of 2 groups were significantly lower than before treatment(P<0.05). The TCM syndrome score, fasting blood glucose, 2h postprandial blood glucose, glycosylated hemoglobin and glucagon levels after treatment of experiment group were significantly lower than control group at the same period(P<0.05). There was no significant difference in the incidence of adverse reactions between 2 groups(P>0.05). Conclusion Qingqian Willow Tea in the treatment of prediabetes patients with Shireyunpi type can effectively control blood sugar level, and has satisfactory safety and the better control effect of this regimen on blood glucose level may be related to its effective inhibition of glucagon secretion.